Edwards Lifesciences' (EW) high-end guidance targets for 2026 are achievable given multiple catalysts ahead, RBC Capital Markets said.

Although the company typically sets guidance conservatively at the start of the year, Edwards has reaffirmed 2026 revenue guidance of $6.4 billion to $6.8 billion and EPS guidance of between $2.90 to $3.05, the brokerage said Tuesday in a research note.

Key 2026 catalysts include updates to transcatheter aortic valve replacement guidelines and the national coverage determination, the US ramp of Sapien M3 for mitral valve replacement and anticipated US Food and Drug Administration approval of Pascal for tricuspid regurgitation, among others.

The investment firm said Edwards' double-digit Q4 revenue growth and continued TAVR momentum support the achievability of its long-range growth plan of about 10% annual revenue growth. It added that Q1 guidance of $1.55 billion to $1.63 billion in revenue and EPS of between $0.70 and $0.76 reflects continued growth into 2026.

RBC reiterated the company's stock rating at outperform, with a $100 price target.

Shares of Edwards Lifesciences were up more than 2% in recent Wednesday trading.

Price: 78.76, Change: +1.71, Percent Change: +2.21